250 related articles for article (PubMed ID: 27026089)
1. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer.
Lennerz JK; van der Sloot KWJ; Le LP; Batten JM; Han JY; Fan KC; Siegel CA; Srivastava A; Park DY; Chen JH; Sands BE; Korzenik JR; Odze RD; Dias-Santagata D; Borger DR; Khalili H; Iafrate AJ; Lauwers GY
Int J Colorectal Dis; 2016 May; 31(5):973-982. PubMed ID: 27026089
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
4. Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study.
Rubio CA; Befrits R
Dis Colon Rectum; 1997 Sep; 40(9):1072-8. PubMed ID: 9293938
[TBL] [Abstract][Full Text] [Related]
5. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
Farchoukh L; Kuan SF; Dudley B; Brand R; Nikiforova M; Pai RK
Am J Surg Pathol; 2016 Oct; 40(10):1390-9. PubMed ID: 27438990
[TBL] [Abstract][Full Text] [Related]
6. Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer.
Sanchez JA; Dejulius KL; Bronner M; Church JM; Kalady MF
Inflamm Bowel Dis; 2011 Sep; 17(9):1966-70. PubMed ID: 21618350
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
9. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
Jin M; Long ZW; Yang J; Lin X
Pathol Oncol Res; 2018 Jan; 24(1):45-57. PubMed ID: 28188432
[TBL] [Abstract][Full Text] [Related]
10. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer.
Takane K; Akagi K; Fukuyo M; Yagi K; Takayama T; Kaneda A
Cancer Med; 2017 May; 6(5):1023-1035. PubMed ID: 28378457
[TBL] [Abstract][Full Text] [Related]
12. Molecular alterations in colitis-associated colorectal neoplasia: study from a low prevalence area using magnifying chromo colonoscopy.
Shivakumar BM; Kumar BL; Bhat G; Suvarna D; Rao L; Pai CG; Satyamoorthy K
J Crohns Colitis; 2012 Jul; 6(6):647-54. PubMed ID: 22398042
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn's and ulcerative colitis based on three decades of experience.
Kiran RP; Khoury W; Church JM; Lavery IC; Fazio VW; Remzi FH
Ann Surg; 2010 Aug; 252(2):330-5. PubMed ID: 20622662
[TBL] [Abstract][Full Text] [Related]
15. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
16. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer complicating inflammatory bowel disease: a comparative study of Crohn's disease vs ulcerative colitis in 34 patients.
Ouaïssi M; Maggiori L; Alves A; Giger U; Sielezneff I; Valleur P; Sastre B; Panis Y
Colorectal Dis; 2011 Jun; 13(6):684-8. PubMed ID: 20184639
[TBL] [Abstract][Full Text] [Related]
18. Colorectal neoplasia in Crohn's colitis: a retrospective comparative study with ulcerative colitis.
Svrcek M; Cosnes J; Beaugerie L; Parc R; Bennis M; Tiret E; Fléjou JF
Histopathology; 2007 Apr; 50(5):574-83. PubMed ID: 17394493
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.
Katafygiotis P; Sakellariou S; Chatziandreou I; Giannopoulou I; Thymara I; Saetta AA; Korkolopoulou P
Anticancer Res; 2019 Nov; 39(11):6379-6387. PubMed ID: 31704871
[TBL] [Abstract][Full Text] [Related]
20. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]